Looking for Kinetico Water Systems? Click Here!

Biopharmaceutical Consulting

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels.

The Biopharmaceutical practice at Kineticos supports clients across three service areas including:

Corporate Strategy

Our Corporate Strategy services combine our in-depth experience and industry knowledge with benchmarks and competitive analysis to help biopharmaceutical companies make critical strategic, financial, and, business development decisions.

Corporate Development

Our Corporate Development services will support and enable biopharmaceutical companies to assess potential opportunities and complete transactions to drive business.

Commercial Strategy

Our Commercial Strategy services help biopharmaceutical companies maximize the commercial value of their products across all phases of the product lifecycle.

Call us today at 888-986-6960 or send an email to Discover How We Can Elevate Your Business

Ready to learn more about Kineticos successes? Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog

 

Case Studies
Articles
Blog

Corporate Strategy

  • Business Model Design

    Situation: A specialty pharmacy company focused in rare hematological disorders needed support and guidance establishing their ex-US commercialization strategy. The sponsor had recently experienced a successful US launch but required support evaluating commercialization models for Canada.  The sponsor established some foundational assumptions regarding the market opportunity but needed specific expertise to tease out the unique … Continue reading Business Model Design »

     

    Read this Case Study

  • Indication Prioritization and Forecasting

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their indication focus.  Their next generation cancer vaccine technology demonstrated early proof of principle in 14 unique tumor types and retained Kineticos to conduct an indication prioritization exercise.  The primary objective of the engagement was to objectively … Continue reading Indication Prioritization and Forecasting »

     

    Read this Case Study

  • Portfolio Optimization

    Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of one of their program’s differentiating attributes. Several indications were under consideration and before further investing in clinical and commercial activities, the sponsor needed to gain insights into available therapies, what drives prescriber decisions, and how … Continue reading Portfolio Optimization »

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus.  Their next generation cancer vaccine technology had applicability to 14 unique cancer tumor types but given the need to narrow their focus, the sponsor retained Kineticos to conduct a portfolio prioritization exercise.  The primary objective … Continue reading Portfolio Prioritization – Oncology »

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the greatest potential to demonstrate patient benefit.  The sponsor was considering 2 tumor types internally and requested that Kineticos conduct a Commercial Assessment to help understand the patient journey, unmet need, and commercial potential of Melanoma … Continue reading Oncology Commercial Assessment – Melanoma »

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and enhance their innovative technology.  Thus, the executive management team hired Kineticos to conduct a scan of the market with a goal of identifying attractive investment opportunities.   Process: Kineticos initially focused on becoming very familiar … Continue reading Product Search »

     

    Read this Case Study

Corporate Development

  • Portfolio Optimization

    Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of one of their program’s differentiating attributes. Several indications were under consideration and before further investing in clinical and commercial activities, the sponsor needed to gain insights into available therapies, what drives prescriber decisions, and how … Continue reading Portfolio Optimization »

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus.  Their next generation cancer vaccine technology had applicability to 14 unique cancer tumor types but given the need to narrow their focus, the sponsor retained Kineticos to conduct a portfolio prioritization exercise.  The primary objective … Continue reading Portfolio Prioritization – Oncology »

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the greatest potential to demonstrate patient benefit.  The sponsor was considering 2 tumor types internally and requested that Kineticos conduct a Commercial Assessment to help understand the patient journey, unmet need, and commercial potential of Melanoma … Continue reading Oncology Commercial Assessment – Melanoma »

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and enhance their innovative technology.  Thus, the executive management team hired Kineticos to conduct a scan of the market with a goal of identifying attractive investment opportunities.   Process: Kineticos initially focused on becoming very familiar … Continue reading Product Search »

     

    Read this Case Study

  • Commercial Assessment

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the greatest potential to demonstrate patient benefit.  The sponsor was considering 2 tumor types internally and requested that Kineticos conduct a Commercial Assessment to help understand the patient journey, unmet need, and commercial potential of Melanoma … Continue reading Commercial Assessment »

     

    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with executing on their partnering strategy.  Thus, Kineticos was retained to lead and manage the business development and licensing process. Process: Kineticos was first charged with developing a clear and concise pitch deck to be leveraged … Continue reading Business Development and Licensing »

     

    Read this Case Study

Commercial Strategy

  • Commercial Strategy

    Situation: A mid-size pharmaceutical company unexpectedly obtained a marketed CNS drug and needed to understand the financial impact of various commercialization strategies. Due to the newly acquired drug being in an adjacent market to the sponsor’s flagship product, there was uncertainty regarding investing in commercialization or eliminating from their product mix.  Given the volatility of … Continue reading Commercial Strategy »

     

    Read this Case Study

  • Portfolio Optimization

    Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of one of their program’s differentiating attributes. Several indications were under consideration and before further investing in clinical and commercial activities, the sponsor needed to gain insights into available therapies, what drives prescriber decisions, and how … Continue reading Portfolio Optimization »

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus.  Their next generation cancer vaccine technology had applicability to 14 unique cancer tumor types but given the need to narrow their focus, the sponsor retained Kineticos to conduct a portfolio prioritization exercise.  The primary objective … Continue reading Portfolio Prioritization – Oncology »

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the greatest potential to demonstrate patient benefit.  The sponsor was considering 2 tumor types internally and requested that Kineticos conduct a Commercial Assessment to help understand the patient journey, unmet need, and commercial potential of Melanoma … Continue reading Oncology Commercial Assessment – Melanoma »

     

    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and executing an outreach strategy designed to secure partnering meetings with key decision makers at biopharmaceutical companies and ultimately, boost revenue for the organization. The sponsor’s technology was validated through existing partnerships and there were internal … Continue reading Business Development & Licensing »

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and enhance their innovative technology.  Thus, the executive management team hired Kineticos to conduct a scan of the market with a goal of identifying attractive investment opportunities.   Process: Kineticos initially focused on becoming very familiar … Continue reading Product Search »

     

    Read this Case Study

  • Primary Research and View of the Future

    “View of the Future.” It’s critical to understand the current landscape for each client’s service offerings, but understanding what respondents recognize as key headwinds and tailwinds in the next 5 years is imperative.” Click here to read the full How To article.

     

    Read this Article

  • A Primer on Immuno-Oncology: Part 1

    In the first part of the Immuno-Oncology Primer, we will provide an overview of anti-cancer vaccines and cytokines before delving into a discussion of immune checkpoint inhibitors. “These successes have refocused attention back on to immunotherapeutic approaches for treating cancer; specifically, the discovery and clinical successes of immune checkpoint inhibitors have revolutionized cancer immunotherapy, and … Continue reading A Primer on Immuno-Oncology: Part 1 »

     

    Read this Article

  • The Disruptor26 Podcast Series with Paul Garofolo

    Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the many species of good bacteria in the body unharmed. Listen to Kineticos Founder and CEO Shailesh Maingi and Paul Garofolo, CEO of Locus Biosciences as they discuss the past, present, and future of Locus Biosciences … Continue reading The Disruptor26 Podcast Series with Paul Garofolo »

     

    Read this Article

  • 2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical

    The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy. The BCI measures c-suite and executive leadership sentiment in the biopharma industry asking questions about their confidence levels concerning key issues. We look for the BCI to become a valuable and highly sought-after resource for … Continue reading 2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical »

     

    Read this Article

  • A Primer on CAR-T Cell Therapy

    “In the world of cancer detection, diagnosis, and treatment, there is a continuous stream of new ideas and inventions that alter our understanding of standards of care and patient outcomes… Although there are many treatment options available, few have received the same level of public attention as chimeric antigen receptor T cell (CAR-T) therapy. CAR-T therapy … Continue reading A Primer on CAR-T Cell Therapy »

     

    Read this Article

  • The FDA’s Shift from Gate Keeper to Enabler

    Soon after Scott Gottlieb announced he was stepping down, he released a statement (Scott Gottlieb’s March 14th, 2019 Statement) that talked about the clinical research landscape and we, at Kineticos, were quite shocked by some of the things that he said. Specifically, former FDA Commissioner Gottlieb stated, “Efforts to streamline medical product development based on … Continue reading The FDA’s Shift from Gate Keeper to Enabler »

     

    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as Roche’s acquisition of Ariosa Diagnostics and LabCorp’s acquisition of Covance, bring to light an important question for decision makers in the life sciences industry: When it comes to growth by acquisition, what is your plan? … Continue reading Growth by Acquisition in Life Sciences: Do You Have a Plan? »

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent blogs, Merck KGaA and Bayer are both responding to the basic core of their original strategies—Merck KGaA is acquiring Sigma-Aldrich to diversify their materials and services and Bayer is “spinning-off” (and eventually selling, over the … Continue reading Merck KGaA and Bayer Choose Opposite Strategies »

     

    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion diagnostic for a Clovis drug currently in clinical trials.1 Specifically, the test is being developed in conjunction with the FDA new drug application submission for Rucaparib, a polymerase inhibitor for the treatment of…

     

    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies have put into oncology, especially the immuno-oncology therapies centered on PD-1. In previous blogs, I noted that BMS appeared to be leaning toward not incorporating a companion diagnostic for nivolumab (another anti-PD-1 therapy) in melanoma … Continue reading Role of Companion Diagnostics in Immuno-oncology Race Unfolding »

     

    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its plastics unit, creating a key shift from chemicals to the life science industry. Along with Merck KGaA, Bayer is one of Europe’s last foremost drug and chemical multinationals, making the shift unprecedented, if not unexpected. … Continue reading Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity »

     

    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute